$PTPI SYMMETRICAL TRIANGLE

٢٨ ديسمبر ٢٠٢١

PTPI: SI 25% |BC 150%
SYMMETRICAL TRIANGLE

Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics. The company engages in the commercialization and development of Stendra, an approved PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a patented topical formulation candidate for the treatment of acute Peyronie's disease; and markets its own line of ED products in the form of vacuum erection device products. The company is based in New York, New York.